Abstract
The present disclosure relates to compositions comprising prostate-specific membrane antigen (PSMA) targeted p50-IMCs and methods of using such PSMA targeted p50-IMCs.
Full Text
What is claimed is:
The present disclosure relates to compositions comprising prostate-specific membrane antigen (PSMA) targeted p50-IMCs and methods of using such PSMA targeted p50-IMCs.
Timeline
Filed
04/30/2026Published
08/27/2026Granted
Not AvailableIPC Codes(7)
A61K 35/15:Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K 39/00; cellular immunotherapy A61K 40/00)
A61K 40/10:characterised by the cell type used
A61K 40/31:Chimeric antigen receptors [CAR]